All the Active Ingredient Drugs
ACE Inhibitor, Thiazide. Hydrochlorothiazide 12.5 mg, 25 mg, Ramipril 2.5 mg, 5 mg. SCORED TABLETS: 30. Accord. desired
antihypertens. effect and pt’s tol. to the
drug. Initial: 2.5 mg ramipril/12.5 mg
HCT, If necess., dose may incr. at
intervals of 2-3 wks. Max. dly dose: 10
mg ramipril/50 mg HCT. Admin. in
morn. as single dose. In most cases,
blood press. will fall suffic. after 2.5 mg
ramipril/12.5 HCT or 5 mg ramipril/25
mg HCT dly. Pts pre-treated with
diuretics: Discont. diuret. at least 2-3
days bef. start. tmt or at least reduc.
diuret. If discont. imposs., initiate tmt.
with smallest possible dose (1.25 mg)
dly in free combinat. Subsequent.
change to dly dose of max. 2.5 mg
ramipril/ 12.5 mg HCT. Ren. impair. pts:
Creatinine clear. 60-30 ml/min/1.73 m2
body surface: Initial: ramipril alone:
1.25 mg dly. Aft. grad. incr. dose, start
combinat. prep: with 2.5 mg
ramipril/12.5 mg HCT dly. Max dly
dose: 5 mg ramipril/25 mg HCT. Impair.
liver funct: Response to tmt. may be
increased/reduced. Tmt. must
therefore be initiated only under close
medic. vis. Max. dly dose: 2.5 mg. Tabs.
to be swallowed whole with liq.
(approx. 1/2 glass) before/during/after
meal. Not to be chewed or crushed.
Not for child.
Essent. hypertens. when blood press.
cannot be adeq. lowered with ramipril
alone.
C/I: Hypersens. to ramipril, any other ACE
inhib., HCT, other thiazide diuret.,
sulfonamides, any other ingred. of the
prep. History angioneurot. edema;
severe impair. ren. funct; dialysis pts, pts.
with hemodynamic. relevant ren. art.
stenos., bilat./unilat. in the single kidney.
Pts. with hemodynamic. relevant leftventric.
inflow/outflow imped. (e.g.
stenos. aort./mitral valve); pts. with clinic.
relevant electrolyte disturbs. which may
worsen follow. tmt, e.g. hypokalem.,
hyponatrem., hypercalcem., severe
impair. liver funct., pregn., lact., concom.
use ACE inhibit., extracorporeal tmt. lead. to contact of blood with negatively
charged surfaces must be avoided (may
lead to severe anaphylact. react.). Such
tmts incl: dialysis or hemofiltrat. with
certain high-flux membranes and low
density lipoprotein apheres. with
dextran sulfate.
ACE Inhibitor. Ramipril 2.5, 5, 10 mg. SCORED TABS: 30 x 2.5 mg; 28, 30 x 5 mg, 10 mg. May be taken irrespect.
of food. Not for child. Hypertens:
Initial. 2.5 mg dly, may be doubled in
2-3 wks. Maint: 2.5-5 mg dly. Max: 10
mg dly. Diuretic or calc. antag. may be
added instead of increas. dose beyond
5 mg dly. Impair. ren. funct: Initial: 1.25
mg dly; max 5 mg dly. Impair. hep.
funct: Init. under med. vis., max. 2.5 mg
dly. CHF: Initial: 1.25 mg dly, may
double to 2.5 mg in 1-2 wks. If 2.5 mg
or more is req., this may be taken as a
single dose or as 2 div. doses; max. 10
mg dly. Impair. ren. funct: 1.25 mg dly;
max. 5 mg dly. Impair. hep. funct:
Initial. under med. vis., max: 2.5 mg dly.
Follow. M.I: Initial: 5 mg dly, in 2 doses
of 2.5 mg morn. and even; if not
tolerat., then 1.25 mg 2 x dly; may be
doubled in 1-3 days; max: 10 mg dly.
Severe NYHA IV heart failure: 1.25 mg 1
x dly. Impair. ren. funct: 1.25 mg dly;
max: 5 mg dly; may be doubled after 1
wk; then after a further 3 wks. increas.
to 10 mg. Maint: 10 mg 1 x dly.
Progress. ren. fail in pts with persist.
proteinuria in excess of 1 g/day: 1.25
mg 1 x dly, to be doubled in 2-3 wks.
No data above 5 mg dly.
Hypertens. CHF, reduct. mortality aft. M.I.
with LV dysfunct., reduce risk M.I., stroke,
CV death, need for revasc. proced. in pts.
over 55 yrs who have clinic. evidence of
CVS dis., stroke or periph. vasc. dis.
Reducing risk of M.I., stroke, CVS death or
need for revasc. proced. diabet. pts over 55
yrs who have: hypertens., high total
cholesterol, low HDL, current smokers; known microalbuminur.; clin. evidence of prev. vasc. dis. Prevent. progress. ren. fail. in pts. with persist. proteinuria in excess of 1 g/day.
C/I: Hypersens. to product or other ACE
inhib.; hist. of angioneurot. edema; pts
with hemodynamic. relev. ren. art.
stenos.; bilat. or unilat. in the single
kidney; pts with hypotens. or
hemodynamic. unstable state. Pregn.,
lactat. Avoid concomit. use of ACE inhib.
and extracorporeal tmts. leading to
contact of blood with negatively
charged surfaces as can lead to severe
anaphylact. reacts. Pts. with
hemodynamic. relev. LV inflow/outflow
impediment.
ACE Inhibitor. Ramipril 10 mg. CAPS: 10 mg.
Hypertens., CHF, reduct. mortality aft.
M.I: Initial. (for pts. not on diuretics):
2.5 mg 1 x dly. May incr. at intervals of
2-3 wks. up to 5 mg 1 x dly to max: 10
mg 1 x dly. Reduct. risk M.I, stroke or
CV death and/or need for
revascularizat: Initial: 2.5 mg 1 x dly.
Depend. On tolerabil. grad. incr. to
double after approx. 1 wk; aft. further
3 wks. incr. to 10 mg. Maint: 10 mg 1 x
dly. Pts already stabilized on lower
doses for other indicats., where
possible should be titrated to 10 mg 1
x dly.
Hypertens. congest. heart fail., reduct.
mortality aft. M.I. with left ventric.
dysfunct., reduce risk M.I., stroke, CV
death, need for revascularizat. in pts. over
55 yrs who have clinical evidence of CV
dis. (prev. M.I., unstable angina,
multivessel CABG or PTCA), stroke or
periph. vasc. dis. Also for reducing risk of
M.I., stroke, CV death or need for
revascularizat. procedures in diabet. pts of
55 yrs or more who have one or more of
the foll. clin. findings: hypertens. (systol.
pressure >160 mm Hg or diastol. pressure
>90 mm Hg); high total cholesterol (>5.2
mmol/L); low HDL (<0.9 mmol/L); current
smoker; known microalbuminur.; clin.
evidence of prev. vasc. dis., prevent.
progress. ren. fail. in pts. suffer. from
impair. ren. funct
ACE Inhibitor. Ramipril 1.25, 2.5, 5 mg. TABS: 28 x 1.25 mg, 2.5 mg, 5 mg.
Hypertens., CCF, reduct. of mortality
aft. M.I: Initial (for pt. not on diuretics):
2.5 mg 1 x dly. May incr. at intervals of
2-3 wks. up to 5 mg 1 x dly. to max. of
10 mg 1 x dly. Reducing risk of M.I.,
stroke or CV death and/or the need for
revascularization procedures: Initial:
2.5 mg 1 x dly. Depend. on tolerability,
dose should be gradually increas. to
double aft. about 1 wk. of tmt; then,
aft. a further 3 wks, increase to 10 mg.
Maint. dose: 10 mg 1 x dly. Pts already
stabilised on lower doses for other
indications where possible should be
titrated to 10 mg 1 x dly.
Hypertens. congest. heart fail., reduct.
mortality aft. M.I., reduce risk M.I., stroke,
CV death, need for revascularizat. in pts.
over 55 yrs who have clinical evidence of
CV dis. (prev. M.I., unstable angina,
multivessel CABG or PTCA), stroke or
periph. vasc. dis. Also for reducing risk of
M.I., stroke, CV death or need for
revascularizat. procedures in diabet. pts
of 55 yrs or more who have one or more
of the foll. clin. findings: hypertens.
(systol. pressure >160 mm Hg or diastol.
pressure >90 mm Hg); high total
cholesterol (>5.2 mmol/L); low HDL (<0.9
mmol/L); current smoker; known
microalbuminur.; clin. evidence of prev.
vasc. dis., prevent. progress. ren. fail. in
pts. with persist. proteinur. in excess of 1
g/day. Not suit. for tmt. hypertens. result.
from prim. hyperaldosteronism.
C/I: hypersens. histor. of angioed.
2nd and 3rd trimester of reg., hypotens.
Sig.bil. renal arter. stenos. See lit.
ACE Inhibitor, Thiazide. Hydrochlorothiazide 12.5 mg, 25 mg, Ramipril 2.5 mg, 5 mg. TABS: 28. Initial: 1 tab dly during or aft.
meals. May incr. at intervals of 2-3 wks.
if reqd. Max. dly dose: 10 mg
ramipril/50 mg HTCZ. See lit.
Essent. hypertens. when a comb. prep. is
indicated.
